Does POLATUZUMAB VEDOTIN Cause Malignant neoplasm progression? 184 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 184 reports of Malignant neoplasm progression have been filed in association with POLATUZUMAB VEDOTIN (POLIVY). This represents 3.9% of all adverse event reports for POLATUZUMAB VEDOTIN.
184
Reports of Malignant neoplasm progression with POLATUZUMAB VEDOTIN
3.9%
of all POLATUZUMAB VEDOTIN reports
32
Deaths
19
Hospitalizations
How Dangerous Is Malignant neoplasm progression From POLATUZUMAB VEDOTIN?
Of the 184 reports, 32 (17.4%) resulted in death, 19 (10.3%) required hospitalization, and 3 (1.6%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for POLATUZUMAB VEDOTIN. However, 184 reports have been filed with the FAERS database.
What Other Side Effects Does POLATUZUMAB VEDOTIN Cause?
Disease progression (1,131)
Off label use (692)
Anaemia (344)
Blood lactate dehydrogenase increased (307)
Drug ineffective (305)
Neutropenia (303)
Death (295)
Covid-19 (286)
Febrile neutropenia (286)
Pyrexia (285)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which POLATUZUMAB VEDOTIN Alternatives Have Lower Malignant neoplasm progression Risk?
POLATUZUMAB VEDOTIN vs POLATUZUMAB VEDOTIN-PIIQ
POLATUZUMAB VEDOTIN vs POLIDOCANOL
POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL
POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL 3350
POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL 3350\POTASSIUM\SODIUM BICARBONATE\SODIUM